Eve Health (ASX:EVE) — Material Events
ASX:EVE · 14 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
EVE Unveils $30B Pipeline of Reformulated Sexual Health and Cardiovascular DrugsMedium
EVE completes reformulated drug R&D targeting $30B+ sexual health and cardiovascular markets, advancing patent filings and licensing strategy
10 Mar 2026
·Research and Development Update
·85
EVE Health Group Launches Libbo™ and Digital Men’s Health Platform in AustraliaMedium
EVE Health Group launches Libbo™ and men's health digital platform in Australia
10 Feb 2026
·Product Launch Announcement
·80
EVE Health Hits Key Milestones with Dyspro™ Prescriptions and Libbo™ ManufacturingMedium
EVE Health achieves first Dyspro™ prescriptions, completes Libbo™ manufacturing, and raises $1.1M to accelerate commercial rollout
30 Jan 2026
·Quarterly Activities and Cash Flow Report
·80
EVE Health Launches Libbo Commercially and Expands Reformulation Pipeline with $1.3M RaiseMedium
EVE Health launches Libbo® commercially, expands pipeline, raises $1.3M
29 Apr 2026
·Quarterly Activities and Cash Flow Report
·80
EVE Health Launches Dyspro™ and Libbo™ with $1.1M Boost for Commercial RolloutMedium
EVE Health advances Dyspro™ and Libbo™ commercialization with $1.1M placement and first patient prescriptions
31 Oct 2025
·Quarterly Activities and Cashflow Report
·80
EVE Health Group Boosts Placement to $1.3M with Strategic Cornerstone InvestorMedium
EVE Health Group secures $1.3M placement with cornerstone investor boost for pharmaceutical reformulation programs
18 Mar 2026
·Capital Raising
·75
Eve Health Accelerates Fast-Acting Pharma with SAS-B Validation and Licensing DealsMedium
Eve Health advances fast-onset pharmaceutical products with SAS-B validation and partner-led commercialisation
26 Mar 2026
·Investor Presentation
·75
EVE Advances Men’s Health with Libbo™ Ready for Market LaunchMedium
EVE completes manufacturing and distribution of Libbo™ for imminent market launch
30 Jan 2026
·Product Launch Announcement
·75
EVE Health Group Elevates Ben Rohr to CEO to Drive Commercial GrowthMedium
EVE Health Group appoints Ben Rohr as CEO, Damian Wood shifts to regulatory role
28 Apr 2026
·Executive Appointment
·70
EVE Health Group Launches $1.3M Capital Raise with Placement Shares and OptionsMedium
EVE Health Group launches $1.3M capital raise with Placement Shares and Options, subject to shareholder approval
20 Mar 2026
·Prospectus
·70
EVE Health Launches Nationwide Telehealth Support for Dyspro and Libbo PatientsMedium
EVE Health partners with hubMed for national telehealth patient support program
19 Nov 2025
·Major Contract Announcement
·70
EVE Advances Libbo Trial and Boosts Apixaban Solubility with New CEO at HelmMedium
EVE advances Libbo pilot study, achieves apixaban solubility milestone, appoints new CEO
7 Aug 2026
·Quarterly Activity and Cash Flow Report
·70
EVE Launches Nationwide Telehealth Support for Dyspro and Libbo PatientsMedium
EVE partners with hubMed to launch national telehealth support program for Dyspro and Libbo patients
19 Nov 2025
·Major Contract Announcement
·70
EVE Health Group Secures $0.9M to Boost Drug Reformulation PipelineMedium
EVE Health Group Raises $0.9M to Advance Drug Reformulation Pipeline
13 Mar 2026
·Capital Raising
·70
No articles in this tier for the last 12 months.
Market Mentions
7
- appeared in market wrap coverage
These are market wrap articles where Eve Health (ASX:EVE) was mentioned. They reflect broader market coverage, not company-specific announcements.
Healthcare Wrap - Week 32 (3 Aug -> 7 Aug) 2026
8 Aug 2026
Healthcare Wrap - Week 18 (27 Apr -> 1 May) 2026
2 May 2026
Healthcare Wrap - Week 13 (23 Mar -> 27 Mar) 2026
28 Mar 2026
Healthcare Wrap - Week 12 (16 Mar -> 20 Mar) 2026
21 Mar 2026
Healthcare Wrap - Week 11 (9 Mar -> 13 Mar) 2026
14 Mar 2026